MedPath

Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty

Not Applicable
Terminated
Conditions
Complications; Arthroplasty, Infection or Inflammation
Wound Complication
Interventions
Device: PREVENA
Registration Number
NCT02355691
Lead Sponsor
University of North Carolina, Chapel Hill
Brief Summary

For the target population of adult patients following primary total hip arthroplasty, the randomized clinical trial will be used to evaluate the efficacy of the use of a mobile negative pressure wound therapy(NPWT) device compared to a standard absorptive dressing in the immediate postoperative period. We will apply two dressing types and evaluate the postoperative wounds with a wound scoring system (ASEPSIS) that incorporates multiple variables of wound infection risk.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • Adult patients undergoing primary total hip arthroplasty.
Exclusion Criteria
  • age less than 18 y/o
  • Total hip arthroplasty for fracture
  • Revision or conversion total hip arthroplasty
  • inability to personally consent to participation due to cognitive impairment, intoxication or sedation
  • multiple surgical procedures
  • Patients taking immune modulating medication(prednisone, methotrexate, anakinra, etc.)
  • skin hypersensitivity to acrylic adhesive or silver.
  • Inability to care for dressing due to physical or mental incapacitation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PREVENA GroupPREVENAPatients will be treated with the PREVENA negative pressure device following total hip arthroplasty. This dressing will be used for a period of seven days.
Primary Outcome Measures
NameTimeMethod
Mean Wound Healing Scores by the ASEPSIS Criteria(Single point evaluation)-2 weeks post surgery visit

A method of evaluating wounds for infection risk that incorporates multiple wound healing factors such as erythema, drainage, and dehiscence is the ASEPSIS (Additional treatment, presence of Serous discharge, Erythema, Purulent exudate, Separation of the deep tissue, Isolation of bacteria, and duration of inpatient Stay) wound scoring system. Originally developed and validated for cardiac surgery sternal wounds, ASEPSIS evaluates the wound for the severity of multiple factors linked with surgical site infection. This includes dehiscence, exudate/discharge, and erythema. The higher the score, the more likely a surgical site infection will be present. This score will give us a more diverse picture of postoperative wound healing and the influence of Negative Pressure Wound Therapy. Scores can range from 0 to 65, with most scores expected at the lower scale.

Secondary Outcome Measures
NameTimeMethod
Number of Participants With Infection(Single point evaluation)-6 weeks post surgery visit

The investigators will continue to monitor the patients for development of an acute postoperative infection. A deep infection refers to an infection below the superficial soft tissue and likely involving the prosthesis. This will be evaluated by the musculoskeletal infection society consensus on total joint infection.

Criteria include:(Either one major criteria or four minor criteria) Major criteria Sinus track communicating with the prosthesis Two separate cultures from the joint positive for the same organism

Minor criteria Elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) Elevated synovial leukocyte count Elevated synovial neutrophil percentage Purulent drainage from the joint One positive fluid culture from the joint Histological analysis of tissue showing more than 5 neutrophils per high power field in 5 fields

Trial Locations

Locations (1)

UNC Orthopaedics

🇺🇸

Chapel Hill, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath